The search for new medications that are both safe and effective weapons in the fight against Alzheimer’s disease has already demanded the collaboration of thousands of researchers and hundreds of thousands of willing subjects. But it is far from over! Since 1998, 146 drugs have been tested and rejected. Only four drugs have made it through the rigorous clinical trial process that precedes approval by the Food and Drug Administration (FDA). The approved drugs have modest symptom-reducing effects, but they do not alter the eventual course of Alzheimer’s disease.
A Recent Disappointment and Renewed Hope
That is why so many patients, caregivers, researchers, and pharmaceutical executives groaned with disappointment in March of this year, when an especially hopeful new medication, aducanumab, was deemed a failure. Plans were made to shut down the two large trials investigating its potential after a few additional months. Aducanumab belongs to the class of drugs known as the anti-amyloid monoclonal antibodies. These molecules, manufactured biologically and injected into research subjects with early Alzheimer’s disease, are like magic bullets targeted at toxic amyloid similar to the way that our own antibodies attack infectious bacteria. In early trials, aducanumab appeared to have disease-modifying properties. When administered to people in an early stage of Alzheimer’s disease, it not only reduced brain amyloid content, it also appeared to delay cognitive decline. No wonder its apparent failure was soupsetti ng.
Using additional data gathered during the final months of study, Biogen revised its earlier assessment. In 2020, an application for approval of aducanumab was submitted to the FDA, seeking permission to market it as an Alzheimer’s disease treatment. In November of 2020, a panel of experts concluded that the clinical data did not support the approval of aducanumab. The FDA’s final decision is anticipated late in March of 2021.
Aducanumab is only one of an estimated 132 Alzheimer medications currently being tested in 670 trials. An overview of these new soldiers in the war against Alzheimer’s was published recently by Dr. Jeffrey Cummings and his colleagues.1 The identification of new targets and new drug mechanisms has researchers busy and hopeful.
Three Areas of Alzheimer’s Medication Research
Disease-modifying biologics are medications produced from living organisms or containing components of living organisms. Vaccines and antibodies are two examples of biologics. These drugs are often large molecules designed to control the actions of other genes, proteins, immune responses, or other cellular processes. The monoclonal antibodies targeting the two hallmarks of Alzheimer’s disease, toxic amyloid and the malfunctioning tau protein, belong to this class. In addition to aducanumab, two other anti-amyloid antibodies still being investigated are solanezumab and gantenerumab.
Disease-Modifying Small Molecules
Disease-modifying small molecules are designed to control biologic processes, are less complex structures that do not originate in living organisms. They are developed in an effort to interfere with multiple disease pathways. Earlier small molecule Alzheimer’s treatments such as the cholinesterase inhibitors and memantine did not modify the course of the disease. Newer small molecule therapies are designed to alter aspects of Alzheimer’s pathology through various mechanisms. Some of these molecules reduce inflammation. Others nurture the growth of synapses, interfere with toxic activities of enzymes, enhance neurotransmission, or improve cellular energy production. Insulin-related molecules, dietary components such as curcumin and omega-3 fatty acids, and tau-active agents such as methylene blue belong to this group.
Symptom-Reducing Small Molecules
Finally, there is a class of symptom-reducing small molecules. Many of these molecules target the non-cognitive behaviors that make caregiving more burdensome. Marijuana components such as nabilone or dronabinol; sleep-enhancing agents such as lemborexant, piromelatine and zolpidem; antidepressants such as escitalopram and mirtazapine; and antipsychotics including brexpiprazole and pimavanserine fall into this category.
Non-Medication Alzheimer's Research
Medications are, of course, only one approach to managing the devastating effects of Alzheimer’s disease. In other areas of research, non-pharmacologic trials continue to explore the effects of treatments such as light therapy, transcranial direct current stimulation, transcranial magnetic stimulation, acupuncture, electroconvulsive therapy, and deep brain stimulation. Special diets, psychosocial therapies, and physical activity are additional areas of inquiry. Psychotherapy and education of caregivers are also being investigated as ways of improving the quality of life for both caregivers and patients. The importance, too, of lifestyle factors has increasingly been recognized and this is being systematically researched.
Much is known about Alzheimer’s disease, but the underlying cause remains obscure. This makes it more difficult to find therapies capable of slowing its course. The amyloid cascade theory, which attributes the disease’s effects to the accumulation of toxic amyloid protein, continues to generate new agents and studies. But additional disease mechanisms are being explored more actively now and may lead to valuable additional or alternate treatment approaches. In order to conquer this disease, scientists, clinicians, research subjects, caregivers, funding agencies, and pharmaceutical companies will need to join their forces. With such a cooperative effort, great strides have already been made in reducing the ravages of cancer, heart disease, stroke, and infection, among other diseases. Many researchers and clinicians envision a future in which the toll that Alzheimer’s disease currently takes will be greatly reduced by a healthier lifestyle and improved therapies.
- Alzheimer’s Disease Toolkit (Helpful Information to Understand and Manage Alzheimer's Disease)
- Expert Information on Alzheimer's Disease (Articles)
- Decreasing Your Risk of Alzheimer’s (Article)
- What are Clinical Trials?—Your Questions Answered (Publication)
- The Phases of Clinical Trials (Article)
- Clinical Trials for Alzheimer’s and Dementia (Interview)
- Treatments for Alzheimer’s Disease (Fact Sheet)
Search for Clinical Trials Near You:
Antidote is a third-party application that allows you to search for clinical trials. It is not affiliated with, or endorsed by, the BrightFocus Foundation or our website. Please see our disclaimer related to third-party sites for more information.
1. For a review of the current “drug development pipeline” consult: Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline:2019. Alzheimer’s & Dementia:Translational Research & Clinical Interventions 2019;5:272-93.
This content was last updated on: November 9, 2020
The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.
These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.
Some of the content may be adapted from other sources, which will be clearly identified within the article.